Product Reports Resources Pricing Login Book a demo

Exelixis

Biotech & Life Sciences · San Francisco, United States · Founded 1994 · IPO 2000

Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer

Valuation $13B
Revenue $2.60B
EBITDA $1.11B
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue

Talent graph

Exelixis's talent

Book a demo to see the people
Employees mapped 1,574 incl. 7 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 12 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on Exelixis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
PaineWebber
Stelios Papadopoulos
Atlas Venture
Oxford Bioscience Partners
Series A 4 investors entered at this stage
Hambrecht & Quist Capital Management
Domain Associates
Pfizer
Advent International
Series B+ 2 investors entered at this stage
University of California
Berkeley

Exelixis mafia

Startups founded by Exelixis alumni

Former Exelixis employees who went on to start their own companies. Sorted by Dealroom signal score.

Quercus BiosolutionsEst. 2024
Jonathan LightnerUnited States
Signal score95
Ventyx BiosciencesEst. 2018
Raju MohanUnited States
Signal score95
Xaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
Signal score92
Grove BiopharmaEst. 2020
Geoffrey M. Duyk, M.D., Ph.D.United States
Signal score90
MiraEst. 2015
SKSylvia KangUnited States
Signal score87
KyvernaEst. 2018
Jeffrey GreveUnited States
Signal score86
Vasa TherapeuticsEst. 2019
Artur PlonowskiUnited States
Signal score80
VectraEst. 2011
Marc RogersUnited States
Signal score78
Good2GoEst. 2015
Fran HellerUnited States
Signal score70
California CulturedEst. 2020
Harrison YoonUnited States
Signal score63
Frame AIEst. 2016
George DavisUnited States
Signal score63
Aerie PharmaceuticalsEst. 2005
CKCasey KopczynskiUnited States
Signal score63

Book a demo to explore the full alumni network →

Global footprint

Where Exelixis has talent and traffic

Workforce by country
13 countries with
team presence
🇺🇸 United States98.1%
🇮🇳 India0.5%
🇫🇷 France0.3%
🇧🇩 Bangladesh0.2%
🇺🇦 Ukraine0.1%
Top 5 of 13 shown
Web traffic by country
150K monthly visits
across markets
🇮🇳 India58.4%
🇺🇸 United States13.3%
🇪🇬 Egypt4.5%
🇵🇭 Philippines4.1%
🇧🇩 Bangladesh2.8%
Top 5 markets shown

Patent intelligence

$140M patent portfolio · 106 active families

Estimated portfolio value
$140M
1.1% of market cap · comparable to top peer Zymeworks ($125M)
106 active patent families
Where Exelixis innovates Cancer researchCell biologyDiseaseGeneMedicinal chemistry

Where Exelixis concentrates vs peers

Each axis is a top-10 topic across Exelixis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Exelixis's 4 investments and acquisitions.

Every disclosed deal where Exelixis appeared as a backer or acquirer, 2000–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Exelixis's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Exelixis's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Exelixis

        An AI-synthesized read of the highest-engagement posts about Exelixis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Exelixis on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles